Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Clinical trial NCT04502394 · RECRUITING

Trial details

NCT number: NCT04502394
Sponsor: Kartos Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Non Hodgkin Lymphoma

Start date: 2021-02-23
Primary completion: 2022-10-01
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.